BRPI0413883A - composição e método para a administração de um composto farmacologicamente ativo a um mamìfero - Google Patents
composição e método para a administração de um composto farmacologicamente ativo a um mamìferoInfo
- Publication number
- BRPI0413883A BRPI0413883A BRPI0413883-0A BRPI0413883A BRPI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A
- Authority
- BR
- Brazil
- Prior art keywords
- active compound
- pharmacologically active
- compositions
- present
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
"COMPOSIçãO E MéTODO PARA A ADMINISTRAçãO DE UM COMPOSTO FARMACOLOGICAMENTE ATIVO A UM MAMìFERO". A presente invenção fornece composições e métodos para ampliar os tempos de liberação e diminuir a toxidez de compostos farmacologicamente ativos. Os compostos consistem num sal do composto farmacologicamente ativo com um íon lipofílico oposto e um solvente farmaceuticamente aceitável imiscível em água. Num modelo, as composições são fornecidas como composições injetáveis. O íon lipofílico oposto pode ser um ácido graxo C~ 8~-C~ 12~,e preferivelmente pode ser um ácido graxo C~ 10~-C~ 18~. As composições são liberadas ao longo do tempo quando administradas a um mamífero. Conseqüentemente, a presente invenção permite que se forneça uma dose de administração controlada do composto ativo por períodos de até 15 dias ou até mais longos. Muitos compostos podem ser administrados de acordo com a presente invenção, incluindo, mas não limitados à tilmicosina, oxitetraciclina, fluoxetina, roxitromicina, e terbinafina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/650,262 US20050049210A1 (en) | 2003-08-27 | 2003-08-27 | Methods for the controlled delivery of pharmacologically active compounds |
PCT/US2004/011823 WO2005025488A2 (en) | 2003-08-27 | 2004-04-16 | Methods for the controlled delivery of pharmacologically active compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413883A true BRPI0413883A (pt) | 2006-10-24 |
Family
ID=34217115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413883-0A BRPI0413883A (pt) | 2003-08-27 | 2004-04-16 | composição e método para a administração de um composto farmacologicamente ativo a um mamìfero |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050049210A1 (pt) |
EP (1) | EP1667654A2 (pt) |
JP (1) | JP2007503433A (pt) |
AU (1) | AU2004271909A1 (pt) |
BR (1) | BRPI0413883A (pt) |
CA (1) | CA2535373A1 (pt) |
WO (1) | WO2005025488A2 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1607937A (zh) * | 2001-10-19 | 2005-04-20 | 爱德士实验室公司 | 用于药理活性化合物的可控释放的可注射组合物 |
US20070196398A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone fatty acid salt compositions |
CN101983632A (zh) * | 2010-10-11 | 2011-03-09 | 西北农林科技大学 | 一种复方替米考星纳米乳抗菌药物及其制备方法 |
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
EP2956121B1 (en) | 2013-02-12 | 2018-05-30 | Bend Research, Inc. | Solid dispersions of low-water solubility actives |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
CN103463480A (zh) * | 2013-08-22 | 2013-12-25 | 邢波 | 一种治疗经络阻塞型急性颈部淋巴结炎的中药制备方法 |
SG10201906474QA (en) * | 2015-02-09 | 2019-09-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of mucositis |
CN107184553A (zh) * | 2017-06-14 | 2017-09-22 | 天津佰力喜动物药业有限公司 | 一种替米考星脂质体分散剂的制备方法 |
CN108392467A (zh) * | 2018-05-30 | 2018-08-14 | 山东德信生物科技有限公司 | 一种替米考星注射液及其制备方法 |
CN109077999A (zh) * | 2018-08-31 | 2018-12-25 | 田红卫 | 一种长效缓释替米考星注射液及其制备方法 |
CN109655534B (zh) * | 2018-11-08 | 2021-11-30 | 佛山市正典生物技术有限公司 | 一种替米考星颗粒含量的检测方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US28875A (en) * | 1860-06-26 | Improvement in desulphurizing ores and coal | ||
ES8104203A1 (es) * | 1979-02-05 | 1981-04-16 | Schering Corp | Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol |
US4235892A (en) * | 1979-02-05 | 1980-11-25 | Schering Corporation, Patent Dept. | 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor |
US4361557A (en) * | 1980-01-28 | 1982-11-30 | Schering Corporation | 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor |
JPS5746986A (en) * | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
US4876352A (en) * | 1988-09-14 | 1989-10-24 | Schering Corporation | Pressurized fluorination of hydroxy alkyl groups |
US5574020A (en) * | 1989-09-28 | 1996-11-12 | Eli Lilly And Company | Tilmicosin formulation |
US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
DK0555340T3 (da) * | 1990-10-25 | 1995-03-06 | Schering Corp | Fremgangsmåde til fremstilling af florfenicol, analoger heraf og oxazolinmellemprodukter dertil |
GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
US5352832A (en) * | 1992-12-18 | 1994-10-04 | Schering Corporation | Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates |
JPH09509141A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | Igf‐iおよびigfbp‐3を投与することによる腎臓疾患処置の方法 |
US6110905A (en) * | 1994-07-09 | 2000-08-29 | Norbrook Laboratories Limited | Long-acting oxytetracycline composition |
US6333021B1 (en) * | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
US6310053B1 (en) * | 1995-07-05 | 2001-10-30 | Norbrook Laboratories Limited | Long-acting oxytetracycline composition |
US5958888A (en) * | 1996-07-02 | 1999-09-28 | Merial, Inc. | Water miscible macrolide solutions |
US5723447A (en) * | 1996-07-02 | 1998-03-03 | Rhone Merieux, Inc. | Water miscible erythromycin solutions |
US5663361A (en) * | 1996-08-19 | 1997-09-02 | Schering Corporation | Process for preparing intermediates to florfenicol |
UA51730C2 (uk) * | 1996-09-04 | 2002-12-16 | Ебботт Лабораторіз | 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців |
US5766506A (en) * | 1996-09-12 | 1998-06-16 | The Dow Chemical Company | Hard water compatible phosphate-containing heat transfer fluids |
SE511313C2 (sv) * | 1997-01-13 | 1999-09-06 | Gs Dev Ab | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
US6239112B1 (en) * | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
US5977133A (en) * | 1998-08-19 | 1999-11-02 | Abbott Laboratories | Pyridone antibiotic with improved safety profile |
US6174540B1 (en) * | 1998-09-14 | 2001-01-16 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated caster oil |
US6140374A (en) * | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
CN1607937A (zh) * | 2001-10-19 | 2005-04-20 | 爱德士实验室公司 | 用于药理活性化合物的可控释放的可注射组合物 |
JP2005531495A (ja) * | 2001-12-21 | 2005-10-20 | シャイア ラボラトリーズ,インコーポレイテッド | 高い物理的安定性を有する経口カプセル製剤 |
-
2003
- 2003-08-27 US US10/650,262 patent/US20050049210A1/en not_active Abandoned
-
2004
- 2004-04-16 JP JP2006524614A patent/JP2007503433A/ja not_active Withdrawn
- 2004-04-16 BR BRPI0413883-0A patent/BRPI0413883A/pt not_active IP Right Cessation
- 2004-04-16 EP EP04816168A patent/EP1667654A2/en not_active Withdrawn
- 2004-04-16 CA CA002535373A patent/CA2535373A1/en not_active Abandoned
- 2004-04-16 WO PCT/US2004/011823 patent/WO2005025488A2/en active Application Filing
- 2004-04-16 AU AU2004271909A patent/AU2004271909A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005025488A2 (en) | 2005-03-24 |
EP1667654A2 (en) | 2006-06-14 |
US20050049210A1 (en) | 2005-03-03 |
WO2005025488A3 (en) | 2005-05-12 |
JP2007503433A (ja) | 2007-02-22 |
AU2004271909A1 (en) | 2005-03-24 |
CA2535373A1 (en) | 2005-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0213425A (pt) | Composições injetáveis para a liberação controlada de composto farmacologicamente ativo | |
US6368618B1 (en) | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs | |
BRPI0413883A (pt) | composição e método para a administração de um composto farmacologicamente ativo a um mamìfero | |
BRPI0512177A (pt) | formulação de liberação modificada de memantina | |
KR20050047525A (ko) | 담체 | |
Rosenblum et al. | Studies in cardiac necrosis: I. Production of cardiac lesions with sympathomimetic amines | |
BR0307540A (pt) | Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo | |
Aljuffali et al. | The codrug approach for facilitating drug delivery and bioactivity | |
PT660707E (pt) | Amantadina e compostos relacionados para utilizacao no tratamento da neuropatia periferica | |
AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
BRPI0518266B8 (pt) | medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular | |
BRPI0711482B8 (pt) | combinação farmacêutica que compreende 3-(3-dimetilamino-1 etil-2-metil-propil) fenol e uma nsaid | |
AR033688A1 (es) | Composicion parenteral reconstituible | |
AR032730A1 (es) | Desnaturalizantes para las sales aminas simpaticomimeticas | |
AR054806A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
CO6190598A2 (es) | Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales | |
NO20085414L (no) | Farmasoytiske preparater for vedvarende frigivelse av fenylefrin | |
BR112013020456B1 (pt) | nova composição antifúngica | |
El Bitar et al. | Neuroprotection by the synthetic neurosteroid enantiomers ent-PREGS and ent-DHEAS against Aβ 25–35 peptide-induced toxicity in vitro and in vivo in mice | |
WO2007117581A2 (en) | Stabilized transdermal bupropion preparations | |
EP1110549A1 (en) | Use of trimebutine for treating pain | |
WO2004091541A3 (en) | Methods for the controlled delivery of pharmacologically active compounds | |
AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
BR0111051A (pt) | Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente | |
BR0013582A (pt) | Agonistas retinóides seletivos para rar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |